A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis (NOVA-BEAM)
An Open-Label, Multicenter, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS).
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
研究联系人备份
- 姓名:Reference Study ID Number BP46580 https://forpatients.roche.com/ No attachments to email below.
- 电话号码:888-662-6728 (U.S. and Canada)
- 邮箱:global-roche-genentech-trials@gene.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Diagnosis of RMS (i.e., relapsing-remitting multiple sclerosis [RRMS] or a secondary progressive multiple sclerosis [SPMS] where patients still experience relapses) in accordance with the revised 2017 McDonald Criteria.
-
No relapse for 30 days prior to screening and neurologically stable with no relapse during screening.
-
Expanded Disability Status Scale (EDSS) score at screening (historical EDSS not older than 6 months may be used), from 0 to 6.5 inclusive.
-
From Part 2 onwards,
- at least two documented clinical relapses within the last 2 years prior to screening, or
- one documented clinical relapse in the year prior to screening or
- one documented clinical relapse together with signs of Magnetic Resonance Imaging (MRI) activity (any T1 Gd+ and/or new or enlarging T2 lesion) between 12 and 24 months prior to screening.
-
Documented MRI of brain with abnormalities consistent with Multiple Sclerosis (MS) at screening.
Exclusion Criteria:
-
History of primary progressive multiple sclerosis (PPMS) at screening.
-
Any of the following laboratory parameters:
- CD4 levels below lower limit of normal (LLN)
- Absolute neutrophil count (ANC) levels below LLN
- Serum immunoglobulin G (IgG) levels below LLN
- Absolute lymphocyte count < 1000 cells per microliter (μL)
- B-cell levels below LLN
-
Known presence of other neurologic disorders that may mimic MS, including but not limited to, neuromyelitis optica spectrum disease, myelin oligodendrocyte antibody associated disease, Lyme disease, untreated vitamin B-12 deficiency, cerebrovascular or spinal vascular disorders, and untreated hypothyroidism.
-
Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, dermatologic, psychiatric, allergic, renal or other major diseases that in the investigator's judgement, may affect interpretation of study results or participant safety.
-
Prior treatment with Chimeric antigen receptor (CAR) T-cell therapy, gene-therapy product, total body irradiation, bone marrow transplantation, allograft organ transplant, or hematopoietic stem cell transplant at any point.
-
Inability to complete an MRI scan (contraindications for MRI, including but not restricted to, pacemaker, cochlear implants, intracranial vascular clips, surgery within 6 weeks prior to screening coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc.) or contraindication to gadolinium administration.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1: Single Ascending Dose Escalation
Participants will receive single dose of RO7845860. |
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol. |
|
实验性的:Part 2: Multiple Ascending Dose Escalation
Participants will receive multiple doses of RO7845860. |
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol. |
|
实验性的:Part 3: Dose Expansion
Participants will receive multiple doses of RO7845860. |
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Part 1, 2 and 3: Incidence and Severity of Adverse Events (AEs)
大体时间:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Part 1, 2 and 3: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Part 1, 2 and 3: Serum Concentration of RO7845860
大体时间:At prespecified timepoints from Baseline up to approximately Week 96
|
At prespecified timepoints from Baseline up to approximately Week 96
|
|
Part 1, 2 and 3: Percentage of Participants Achieving B-Cell Levels Below the Lower Limit of Quantitation in Blood as per Employed High-Sensitive Flow Cytometry Assay
大体时间:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Part 1, 2 and 3: B-Cell Levels Over Time in Blood
大体时间:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Parts 1, 2 and 3: Median Time to Repletion of B-Cells in Blood to the Lower Limit of Normal or to the Detection Limit of the B-cell Assays
大体时间:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Parts 2 and 3: Change From Baseline in B-Cell Levels in Cerebrospinal Fluid (CSF)
大体时间:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
|
Parts 1, 2 and 3: Prevalence and Incidence of Anti-drug Antibodies (ADAs) to RO7845860
大体时间:From Baseline up to approximately Week 96
|
From Baseline up to approximately Week 96
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- BP46580
- 2026-526353-34-00 (其他标识符:EU CT Number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.